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  INTRODUCTION 
 Hepatocellular carcinoma (HCC) is the fi  ft  h most common malig-
nant neoplasm in the world (  1  ). Only 20  %   of HCC patients are 
candidates for resection (  2  ). Furthermore, recurrence is frequent 
even aft  er apparently curative resection. Liver transplantation 
is restricted by organ donor shortage. Th  us, various nonsurgi-
cal therapies have been introduced (  3  –  5  ). Among these, image-
guided percutaneous ablation is considered best for early-stage 
HCC. 
  Ethanol injection was formerly the standard procedure among 
the various percutaneous ablation techniques. Randomized con-
trolled trials, however, have demonstrated that radiofrequency 
ablation (RFA) has a more reliable local antitumor eff  ect, leading 
to a lower local tumor progression risk and higher survival rates 
(  6  –  9  ). RFA has largely replaced ethanol injection (  10  ). 
  Several reports on 5-year outcome of RFA exist (  11  –  17  ); how-
ever, no study has covered 10-year outcome. We report on a 10-year 
consecutive case series at a tertiary referral center. We analyzed 
antitumor eff  ect, patient survival, local tumor progression, and 
distant recurrence rates, variables relevant to these outcomes, and 
complications. To our knowledge, this study documents the largest 
number of RFA treatments performed at a single institution.     
  METHODS   
  RFA indications 
  RFA was the treatment of choice in HCC patients satisfying the 
following criteria: (i) ineligible for surgical resection  /  liver trans-
plantation or patient refusal for surgery; (ii) no extrahepatic 
metastasis  /  vascular invasion; and (iii) no other malignancies that 
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may determine the patient  ’  s prognosis. Exclusion criteria were as 
follows: (i) tumor not visualized by ultrasonography  /  not accessi-
ble percutaneously; (ii) total bilirubin level   ≥ 3.0   mg / dl;  (iii)  plate-
let count     <    50 × 10 9  / l or prothrombin activity     <    50 % ; (iv) refractory 
ascites; (v) enterobiliary refl  ux; and (vi) adhesion between the 
tumor and the gastrointestinal tract. In general, we performed 
RFA on Child-Pugh class A or B patients, a single tumor   ≤ 5   cm 
in diameter, or three or fewer tumors   ≤  3     cm in diameter. In cases 
beyond these conditions, we performed RFA on patients who were 
likely to benefi  t from this procedure for possible cure or prolonga-
tion of life. No patients were excluded solely on account of tumor 
location (  18  ). Informed consent was obtained from each patient. 
Th   is study was conducted according to the ethical guidelines of 
the 1975 Declaration of Helsinki and approved by the institutional 
review board (Registration ID: P98C05-11Y).     
  Patients 
  In this cohort study, we analyzed a prospectively collected com-
puterized database. Between February 1999 and December 2009, 
2,825 HCC patients were admitted once or more to the Depart-
ment of Gastroenterology, the University of Tokyo (  Figure 1 ).  At 
initial hospitalization, 1,485 had primary HCC and the remaining 
1,340 had recurrent HCC. In the recurrent HCC patients, primary 
HCC had previously been treated by therapies other than RFA. 
  Of the 1,485 primary HCC patients, 1,294 (87.1  %  ) underwent 
percutaneous ablation as the initial treatment, including RFA. Th  e 
remaining 191 patients underwent other therapies: hepatic resec-
tion, 29 patients with good liver function and who consented to 
an operation; transarterial chemoembolization, 149 with multin-
odular or large tumors that could not be treated by ablation thera-
pies; systemic chemotherapy, three with extrahepatic metastasis; 
and only supportive care, 10 with decompensated cirrhosis or poor 
general condition. 
  Of the 1,294 patients treated by percutaneous ablation, 1,170 
underwent RFA and the other 124 underwent ethanol injection. 
Th  e choice of therapy was made as follows: between April 1999 
and January 2001, 232 patients with three or fewer tumors, each 
  ≤  3      cm in diameter, and Child-Pugh class A or B liver function 
were entered into a randomized controlled trial to compare RFA 
with ethanol injection (  6  ). Patients outside these inclusion crite-
ria were mostly treated by RFA. Aft  er this trial, RFA was generally 
the treatment of choice, and ethanol injection was administered 
only to those considered unsuitable for RFA; ethanol injection was 
administered to those with either enterobiliary refl  ux or adhesion 
of the tumor to the gastrointestinal tract. 
  HCC was diagnosed based on typical imaging fi  ndings; that 
is, early-phase enhancement and late-phase contrast washout on 
dynamic computed tomography (CT) (  19  ). HCC diagnosis was 
also confi  rmed by biopsy in 1,078 (92.1  %  ) of the 1,170 patients 
with RFA-treated primary HCC. A total of 998 (85.3  %  ) were diag-
nosed as having liver cirrhosis. 
  In general, transarterial chemoembolization was combined 
with RFA in patients with either   ≥  4 tumors or those with even 
one  tumor      >    3.0   cm  in  diameter,  although  indication  criteria  of 
this combination had changed over time. Th  e combination of 
trans  arterial chemoembolization with RFA was performed in 324 
primary HCC patients.     
  Treatment methods 
  RFA was performed on an inpatient basis. Preoperative planning 
including evaluation of all imaging studies, and careful ultrasound 
examination was performed to identify the tumors and determine 
the access routes. 
 Th  e procedure was performed according to an institutional 
protocol and in the presence of three physicians. One physician 
inserted the electrode under ultrasound guidance while another 
assisted the procedure; at least one had 8-year or longer experience 
of percutaneous ablation therapies. Th   e remaining physician was 
responsible for the ultrasound machine and data recording. Video 
recording was performed occasionally to improve and standardize 
the procedure. 
 Th  e precise techniques of RFA are described elsewhere (  6  ). 
Briefl  y, all RFA procedures were performed percutaneously under 
ultrasound guidance (Power Vision 8000, Aplio XV or Aplio XG; 
Toshiba, Tokyo, Japan). We used artifi  cial pleural eff  usion (  20  ) or 
artifi  cial ascites ( 21 ) for tumors, which were in the hepatic dome or 
adjacent to the gastrointestinal tract. Aft  er administration of seda-
tives and local anesthesia, a 17-gauge cooled-tip electrode (Cool-
Tip; RF Ablation System, Covidien, Boulder, Colombia, CO) was 
inserted. Radiofrequency energy was delivered for 6  –  12      min for 
each application. For large tumors, the electrode was repeatedly 
inserted into diff  erent sites, such that the entire tumor could be 
enveloped by assumed necrotic volumes. Following the procedure, 
the patient remained in bed until the next morning. 
  A CT scan with a 5-mm section thickness was performed 1  –  3 
days aft  er RFA to evaluate technique eff   ectiveness  ( 22 ).  Complete 
ablation was defi  ned as hypoattenuation of the entire tumor. We 
intended to ablate not only the tumor but also some of the liver 
Hospitalized HCC patients (n=2,825)
Hospitalized for treatment of primary
HCC (n=1,485)
Hospitalized for treatment of recurrent
HCC (n=1,340)
Ethanol injection (n=124)
Radiofrequency ablation (n=1,170)
Percutaneous ablation therapies
(n=1,294)
Hepatectomy (n=29)
Transarterial chemoembolization (n=149)
Systemic chemotherapy (n=3)
Best supportive care (n=10)
    Figure 1  .                 Flow of patients in this study. HCC, hepatocellular carcinoma.   © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
571
 
L
I
V
E
R
 
  Radiofrequency Ablation for HCC: 10-Year Outcome 
parenchyma surrounding it. When we suspected that unablated 
tumor portions remained, the procedure was repeated. We did 
not predefi  ne the procedure number in a treatment: treatment was 
generally continued until CT imaging demonstrated necrosis of 
the entire tumor.     
  Follow-up 
 To detect recurrence at an early stage, serum  α -fetoprotein (AFP), 
lectin-reactive AFP (AFP-L3), and des-  γ -carboxy-prothrombin 
(DCP) levels were measured monthly, and CT and ultrasonogra-
phy were performed every 4 months. Local tumor progression was 
defi  ned as the appearance of viable cancer tissue touching the ini-
tially treated tumor (  22  ) and distant recurrence as the emergence 
of one or several tumor(s) separate from the primary site. Chest 
CT or bone scintigraphy was performed if extrahepatic recur-
rence was suspected. RFA was used for recurrence if the patient 
still met the indication criteria. If multiple recurrences were not 
treatable with RFA, transarterial chemoembolization was gener-
ally  performed.   
  Statistical analysis 
 Th  is is a report of a consecutive case series: all RFA treatments 
performed on primary HCC patients at the Department of Gas-
troenterology, University of Tokyo between February 1999 and 
December 2009 were included and none was excluded. Data are 
presented as mean  ±  s.d. for quantitative variables, and as absolute 
frequencies for qualitative variables. 
 A  “ procedure ”  was defi  ned as a single intervention episode com-
prising one or more ablation performed on one or more tumors 
and a   “  treatment  ”   as the completed eff  ort to ablate one or more 
tumors. A treatment comprised one or more procedures (  22  ). 
  “ Technique  eff  ectiveness  ”   rate was defi  ned as the percentage of 
successfully eradicated macroscopic tumors, as evidenced by CT 
scan 1  –  3 days aft  er the last procedure (  22  ). 
  Overall survival was calculated in the 1,170 primary HCC 
patients. Survival curves were generated by the Kaplan  –  Meier 
method. In addition to overall survival, some subgroup analy-
ses were performed with clinical characteristics including tumor 
size, tumor number, and liver function. Recurrence was evaluated 
in 1,138 of the 1,170 primary HCC patients; the remaining 32 
patients were excluded from the recurrence analysis because some 
small tumors had been left   untreated by RFA on account of detec-
tion failure by ultrasonography. Recurrence rates were calculated 
by the Gaynor  ’  s method (  23  ). All time estimates were made from 
the date of the fi  rst RFA. Th   e follow-up was fi  nalized at either death 
or the last visit to the outpatient clinic before 31 December 2009. 
Transplanted patients were censored from this study at the date of 
transplantation. 
 Th   e prognostic relevance of 19 baseline variables (  Table 1 ),  the 
combination of transcatheter arterial chemoembolization (TACE) 
with RFA, HCC recurrence, and the number of RFA sessions to 
survival was analyzed by univariate and multivariate Cox propor-
tional hazards regression models. Th   e prognostic relevance of 19 
baseline variables (  Table 1  ), the combination of TACE with RFA, 
and the number of RFA sessions to local tumor progression and 
distant recurrence was also analyzed by univariate and multivari-
ate models. All variables with a   P   value      <    0.05  by  univariate  com-
parison were subjected to multivariate analysis. Some continuous 
variables in which log-linearity could not be assumed were trans-
formed into categorical variables. In multivariate analysis, we 
evaluated two models that contained either Child-Pugh class or its 
components to avoid multicollinearity. A stepwise variable selec-
tion was performed with Akaike Information Criteria in multivari-
ate analysis. Th   e results of multivariate analyses were presented as 
a hazard ratio with corresponding 95  %   confi  dence interval (CI), 
with   P   values from the Wald test. All signifi  cance tests were two-
tailed, and diff  erences with a   P   value      <    0.05  were  considered  statis-
tically signifi  cant. 
 Complications  were  defi  ned according to the guidelines of the 
Society of Interventional Radiology (  24  ).       
  RESULTS   
  Antitumor effect 
  We performed a total of 2,982 RFA treatments for the 1,170 pri-
mary HCC patients, comprising 4,514 procedures. Th  us,  procedure 
number per treatment was 1.52  ±  0.78. Many patients undergoing 
RFA for treatment of primary HCC received iterative RFA treat-
ments for recurrence. A total of 485 patients underwent RFA treat-
ment once, 247 twice, 177 thrice, 94 four times, 70 fi  ve times, 35 six 
times, 23 seven times, 14 eight times, 7 nine times, 7 ten times, 6 
eleven times, 2 twelve times, 2 thirteen times, and 1 fourteen times. 
 Technique eff   ectiveness rate was 99.4 %  (2,964 / 2,982 treatments). 
It was similar between the initial RFA treatments and the other 
RFA treatments for recurrence (  P     =    0.98).  Complete  ablation  of  the 
tumor was achieved in 1,163 (99.4 % ) of the 1,170 initial treatments 
and in 1,801 (99.4  %  ) of the 1,812 other RFA treatments. However, 
technique eff  ectiveness rate signifi  cantly diff  ered with tumor size 
(  P     =    0.023).  No  apparent  viable  portions  remained  in  the  treated 
tumor in 1,642 (99.6  %  ) of 1,648 treatments for tumors   ≤ 2.0   cm  in 
diameter, in 923 (99.2  %  ) of 930 treatments for tumors 2.1  –  3.0     cm, 
in  356  (98.9 % )  of  360  treatments  for  tumors  3.1 – 5.0   cm,  and  in 
43  (97.7 % )  of  44  treatments  for  tumors      >    5.0   cm.  Final  CT  imag-
ing demonstrated residual cancer tissue in the remaining 18 treat-
ments. We decided against performing additional procedures, 
because liver failure rather than HCC seemed to determine the 
prognosis in 10 treatments, and because additional RFA would 
have caused complications on account of poor visualization or 
inaccessibility in the other eight treatments.     
  Survival 
 Th   e 19 baseline clinical characteristics of the 1,170 patients who 
underwent RFA for treatment of primary HCC are shown in 
  Table 1 .  A  total  of  269  patients  (23.0 % )  were      >    75  years  old.  In  all, 
422 patients had tumors  ≤ 2.0   cm in diameter, 467 had tumors 2.1 –
 3.0   cm,  246  had  tumors  3.1 – 5.0   cm,  and  35  had  tumors      >    5.0   cm; 
685 patients had 1 tumor, 395 had 2 or 3 tumors, and 90 had   ≥ 4 
tumors. 
 As of December 2009 (with a median follow-up of 38.2 months), 
692 patients (59.1  %  ) remained alive, 39 (3.3  %  ) were lost to The American Journal of GASTROENTEROLOGY  VOLUME 107 | APRIL 2012   www.amjgastro.com
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 follow-up, and 439 (37.5 % ) had died. Of the 1,170 patients, two were 
transplanted. Th   e number of 5-, 7-, and 10-year survivors was 325, 
131, and 16, respectively. Th   e cause of death was HCC in 245 patients 
(55.8 % ), liver failure in 89 (20.3 % ), upper gastrointestinal bleeding in 
11 (2.5  %  ), complications related to the procedure in 3 (0.7  %  ), liver-
unrelated diseases in 81 (18.5  %  ), and undetermined in 10 (2.3  %  ). 
 Th   e 1-, 3-, 5-, 7-, and 10-year survival rates of all 1,170 primary 
HCC  patients  were  96.6 %   (95 %   CI:  95.5 – 97.7 % ),  80.5 %   (95 %   CI: 
78.0 – 83.1 % ),  60.2 %   (95 %   CI:  56.7 – 63.9 % ),  45.1 %   (95 %   CI:  40.9 –
 49.6 % ),  and  27.3 %   (95 %   CI:  21.5 – 34.7 % ),  respectively  ( Figure 2 ; 
  Table 2  ). Survival rates diff  ered  signifi   cantly with tumor size 
(  P     <    0.0001),  tumor  number  ( P     =    0.0003),  and  Child-Pugh  class 
(  P         <       0.0001). In the Child-Pugh class A or B patients with a single 
tumor  ≤ 5   cm in diameter, or three or fewer tumors  ≤ 3   cm in diame-
ter, the 5-year survival rate was 63.8  %   (95  %   CI: 59.9  –  67.9  %  ), while 
in those outside these criteria, it was 46.4  %   (95  %   CI: 39.4  –  54.8  %  ). 
  Univariate analysis showed 19 of the 22 variables relevant to 
survival. In multivariate analysis that contained Child-Pugh class 
but not its components, a model that contained age, antibody to 
hepatitis C virus (anti-HCV), Child-Pugh class, tumor size, tumor 
number, serum DCP level, and serum AFP-L3 level was selected 
(  Table 3 ).  Th  e other model that contained the components of 
Child-Pugh class is shown in   Supplementary Table online .   
  Recurrence 
  Recurrence developed in 741 patients. Local tumor progression 
alone was found in 25, local tumor progression with distant recur-
rence was found in 9, and distant recurrence alone was found in 
the other 707 patients. Of these 707 patients, 13 had the fi  rst recur-
rence in extrahepatic sites: 7 had lymph node metastasis, 3 had 
peritoneal seeding, 1 had lung metastasis, 1 had bone metastasis, 
and the remainder had both peritoneal seeding and lung metasta-
sis. No recurrence developed in the remaining 397 patients. 
  Of the 741 patients, the fi  rst recurrence was treated by iterative 
RFA in 659 (88.9 % ), transarterial chemoembolization in 69 (9.3 % ), 
systemic chemotherapy in 4 (0.5  %  ), surgical resection in 3 (0.4  %  ), 
radiation therapy in 2 (0.3  %  ), and supportive care in 4 (0.5  %  ). 
        Table 1  .       Baseline characteristics of the 1,170 patients undergoing 
radiofrequency ablation for primary hepatocellular carcinoma     
        Variable      
      Age (years)    68.3  ±  8.6 
      Males,   n   (  %  )   751 (64.1) 
        Viral infection   
           HBs-Ag-positive,   n   (  %  )   127 (10.9) 
           Anti-HCV-positive,   n   (  %  )   870 (74.4) 
           Both positive,   n   (  %  )   13 (1.1) 
           Both negative,   n   (  %  )   159 (13.6) 
      Alcohol consumption       >      80    g  /  d   170 (14.5) 
      Ascites,   n   (  %  )   117 (10.0) 
      Encephalopathy,   n   (  %  )   24 (2.1) 
      Albumin (g  /  dl)   3.65  ±  0.47 
      Total bilirubin (mg  /  dl)   0.95  ±  0.49 
      Prothrombin time (  %  )   79.6  ±  14.1 
      Platelet count (  ×  10  4    /  mm  3  )   11.9  ±  5.6 
          AST (IU  /  l)   61.5  ±  35.9 
          ALT (IU  /  l)   57.3  ±  40.8 
        Child-Pugh class,   n   (  %  )   
           A   868 (74.2) 
           B   291 (24.9) 
           C   11 (0.9) 
          Tumor size (cm)    2.54  ±  1.04 
          Tumor number    1.8  ±  1.2 
        Serum AFP (ng  /  dl),   n   (  %  )   
             ≤  100   928 (793) 
           101  –  400   146 (12.5) 
                 >      400   96 (8.2) 
        Serum DCP (mAU  /  ml),   n   (  %  )      a     
             ≤  100   964 (83.1) 
           101  –  400   126 (10.9) 
                 >      400   70 (6.0) 
            Serum AFP-L3 (  %  ),   n   (  %  )   
             ≤  15   1,015 (86.8) 
           15.1  –  40   74 (6.3) 
                 >      40   81 (6.9) 
          AFP,   α  -fetoprotein; AFP-L3, lectin-reactive   α  -fetoprotein; ALT, alanine 
aminotransferase; AST, asparatate aminotransferase; DCP, des-  γ  -carboxy-pro-
thrombin; HCV, hepatitis C virus.     
          Data are expressed as mean  ±  s.d.     
      a        Serum DCP level could not be measured in 10 patients because they were 
being administered warfarin.     
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    Figure 2  .                 Overall survival in 1,170 primary hepatocellular carcinoma 
patients who underwent radiofrequency ablation.   © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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died of hepatic failure on account of massive hepatic infarction 
7 days aft  er the last RFA procedure. He had undergone 12 RFA 
treatments in 8 years. Th   e treatment mortality rate was 0.03  %  .       
  DISCUSSION 
 Th   is study describes our 10-year clinical experience with RFA at a 
high-volume center. We performed the 2,982 RFA treatments on 
a total of the 1,170 primary HCC patients, showing that RFA has 
a high antitumor eff  ect. Tumors were judged to have been com-
pletely ablated by fi  nal CT imaging in 99.4  %   of the treatments. 
Complete response was achieved not only in the fi  rst RFA but also 
in iterative RFA for recurrence. Although complete response rate 
diff  ered with tumor size, there was not a sharp drop-off   in eff  ec-
tiveness. Th   e complete response rate may be higher in this study 
than others probably because we generally repeated the procedure 
until CT imaging demonstrated complete tumor necrosis, whereas 
many other studies limited the procedure number of RFA to 2  –  3 
(  11,13,15  ). Complete ablation of tumors has been reported to be 
related to improved survival (  25  ). Th   ere were the 18 treatments 
in which we did not perform additional RFA for residual cancer 
tissue. In those treatments, usefulness of RFA had been unclear at 
the initial session because of liver dysfunction or tumor burden. 
 Th   e 1-, 3-, 5-, 7-, and 10-year rates of local tumor progression 
with or without distant recurrence were 1.4  %   (95  %   CI: 0.7  –  2.1  %  ), 
3.2 %   (95 %   CI:  2.1 – 4.3 % ),  3.2 %   (95 %   CI:  2.1 – 4.3 % ),  3.2 %   (95 %   CI: 
2.1 – 4.3 % ),  and  3.2 %   (95 %   CI:  2.1 – 4.3 % ),  respectively  ( Figure 3 ). 
Univariate analysis demonstrated that prothrombin time and 
serum AFP, DCP, and AFP-L3 levels were correlated to local tumor 
progression, whereas multivariate analysis showed that serum 
DCP level alone was signifi  cantly correlated. Tumor size was not 
correlated to local tumor progression. 
 Th   e 1-, 3-, 5-, 7-, and 10-year rates of distant recurrence without 
local  tumor  progression  were  25.6 %   (95 %   CI:  23.0 – 28.2 % ),  63.3 %  
(95 %   CI:  60.2 – 66.4 % ),  74.8 %   (95 %   CI:  71.8 – 77.8 % ),  78.1 %   (95 %  
CI:  75.1 – 81.2 % ),  and  80.8 %   (95 %   CI:  77.4 – 84.3 % ),  respectively. 
Univariate analysis demonstrated 14 variables relevant to distant 
recurrence, whereas multivariate analysis showed that anti-HCV, 
Child-Pugh class, platelet count, tumor size, tumor number, serum 
AFP level, and serum DCP level were signifi  cantly related to dis-
tant recurrence (  Table 3 ).   
  Complications 
  A total of 67 complications were encountered (  Table 4 ).  Th  e  inci-
dence rates of complications per treatment and per procedure were 
2.2 %   (67 / 2,982)  and  1.5 %   (67 / 4,514),  respectively.  One  patient 
    Table 2  .       Survival of patients undergoing radiofrequency ablation, based on tumor number, tumor size, and Child-Pugh class      
        Grading         n         Survival (  %  )       Median (years)         P       value   
              1-Year       3-Year       5-Year       7-Year       10-Year         
      Overall survival    1,170   96.6   80.5   60.2   45.1   27.3   6.4     —   
        Tumor number   
           Solitary   685   97.2   82.6   64.6   50.5   32.0   7.0   0.0003 
           2  –  3   395   95.7   77.9   54.4   39.4   19.9   5.6    
             ≥  4   90   96.5   76.4   53.6   30.1   17.6   5.3    
        Tumor size   
             ≤  3    cm   889   97.2   83.8   65.1   47.3   30.7   6.7         <      0.0001 
                 >      3    cm   281   94.8   71.0   46.5   38.0   18.6   4.6    
        Child-Pugh class   
           A   868   98.0   86.0   65.9   50.2   30.1   7.0         <      0.0001 
           B   291   93.2   66.4   46.5   32.4   20.6   4.6    
           C   11   81.8   58.4   23.4   23.4       —       3.1    
        Combination of tumor number, tumor size, and Child-Pugh class   
           Solitary,   ≤  3    cm   534   97.6   84.7   68.0   51.4   34.3   7.1       —     
           Solitary,   ≤  3    cm, Child-Pugh A    401   98.7   90.1   74.0   57.4   41.3   8.2       —     
           1  –  3 Tumors,   ≤  3    cm   822   97.1   83.7   65.2   48.8   32.5   6.9       —     
           Solitary,   ≤  5    cm, or 1  –  3 tumors,   ≤  3    cm   947   97.2   82.8   63.8   48.8   30.6   6.9       —     
        Child-Pugh A  /  B   
             Satisﬁ  ed the indication criteria of surgical 
resection proposed in the BCLC protocol    a     
  237   98.6   90.5   75.9   61.1   38.1   8.7       —     
          BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma.     
      a        Child-Pugh class A with a normal level of bilirubin, no signiﬁ  cant portal hypertension, and a single HCC.     The American Journal of GASTROENTEROLOGY  VOLUME 107 | APRIL 2012   www.amjgastro.com
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 Th  is study shows that RFA could achieve long-term survival 
for as long as 10 years. Sixteen patients treated by RFA survived 
for      >    10  years.  Th  e variables relevant to survival were similar to 
those found in previous studies on ethanol injection (  26,27  ), RFA, 
hepatic resection (  28  ), and transarterial chemoembolization (  29  ). 
Both liver function and tumor-related factors were associated with 
survival. In addition, age and anti-HCV were relevant to survival 
in this study. Age was among the prognostic factors, probably 
because 23.0  %   of the patients were        >       75 years old, which resulted 
in a higher percentage (18.5  %  ) of liver-unrelated deaths in this 
study compared with others. Anti-HCV was among the prognostic 
factors, probably because anti-HCV-positive patients developed 
distant recurrence more frequently. 
  HCC frequently recurred aft  er RFA; most recurrences were, 
however, not local tumor progression but distant recurrence. Fre-
quent recurrence is not specifi  c to RFA. Aft  er hepatic resection, the 
      Table 3  .       Multivariate analysis of variables relevant to survival, 
local tumor progression, and distant recurrence     
        Variable   
    Multivariate analysis   
  Hazard ratio (95  %   CI)          P   value   
          Survival     
           Age (per year)    1.03 (1.02  –  1.04)         <      0.0001 
           Anti-HCV-positive   1.34 (1.03  –  1.76)   0.03 
       Child-Pugh class 
           A   1    
           B or C    2.08 (1.69  –  2.56)         <      0.0001 
       Tumor size (cm) 
             ≤  2.0   1    
           2.1  –  3.0   1.40 (1.10  –  1.80)   0.007 
           3.1  –  5.0   1.80 (1.37  –  2.38)         <      0.0001 
                 >      5.0   1.50 (0.90  –  2.49)   0.12 
       Tumor number 
           Solitary   1    
           2  –  3   1.28 (1.04  –  1.59)   0.02 
             ≥  4   1.58 (1.13  –  2.21)   0.008 
       Serum DCP (mAU  /  ml) 
             ≤  100   1    
           101  –  400   1.22 (0.88  –  1.69)   0.24 
                 >      400   1.66 (1.14  –  2.42)   0.008 
       Serum AFP-L3 (  %  ) 
             ≤  15   1    
                 >      15   1.45 (1.11  –  1.91)   0.008 
        Local tumor progression   
       Serum DCP (mAU  /  ml) 
             ≤  100   1    
           101  –  400   2.51 (1.02  –  6.20)   0.05 
                 >      400   6.52 (2.63  –  16.1)         <      0.0001 
        Distant recurrence   
           Anti-HCV-positive   1.44 (1.19  –  1.75)   0.0002 
       Child-Pugh class 
           A   1    
           B or C    1.23 (1.03  –  1.45)   0.02 
       Platelet count (  /  l) 
                 >      10  11     1    
             ≤  10  11     1.36 (1.12  –  1.64)   0.002 
       Tumor size (cm) 
             ≤  2.0   1    
           2.1  –  3.0   1.30 (1.10  –  1.55)   0.003 
           3.1  –  5.0   1.29 (1.05  –  1.60)   0.02 
                 >      5.0   1.25 (0.75  –  2.08)   0.4 
      Table 3  .       Continued     
        Variable   
    Multivariate analysis   
  Hazard ratio (95  %   CI)          P   value   
       Tumor number 
           Solitary   1    
           2  –  3   1.36 (1.16  –  1.59)   0.0002 
             ≥  4   2.02 (1.53  –  2.66)         <      0.0001 
       Serum AFP (ng  /  dl) 
             ≤  100   1    
           101  –  400   1.15 (0.92  –  1.44)   0.22 
                 >      400   1.36 (1.03  –  1.81)   0.03 
       Serum DCP (mAU  /  ml) 
             ≤  100   1    
           101  –  400   1.19 (0.92  –  1.54)   0.19 
                 >      400   1.72 (1.22  –  2.42)   0.002 
          AFP,   α  -fetoprotein; CI, conﬁ  dence interval; DCP, des-  γ  -carboxy-prothrombin; 
HCV, hepatitis C virus.     
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    Figure 3  .                 Local tumor progression and distant recurrence in patients who 
underwent radiofrequency ablation.   © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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because  the  number  of  patients  with  tumors      >    5.0   cm  ( n     =    35)  were 
not large enough for the diff  erence to be statistically signifi  cant. 
Another possibility is selection bias. It is possible that patient with 
tumors      >    5.0   cm  who  underwent  RFA  had  more  favorable  condi-
tions for survival and distant recurrence except tumor size than 
those  with  2.1 – 5.0   cm  tumors. 
  In this study, 324 of the 1,170 patients were treated with combi-
nation of TACE and RFA at the initial treatment. Th   us, we evalu-
ated the combination as a possible variable that infl  uences survival 
or recurrence. Univariate analysis demonstrated that the combined 
therapy was signifi  cantly correlated to overall survival, whereas 
multivariate analysis did not show the relationship. TACE was 
generally combined with RFA in patients with either   ≥ 4  tumors 
or those with even one tumor         >        3.0      cm in diameter. Th  is is why 
the correlation was signifi  cant in univariate analysis, while it was 
not in multivariable model in which the eff  ect of other risk factors, 
such as tumor number and tumor size were adjusted. Th  e com-
bination of TACE and RFA was not signifi  cantly related to either 
local tumor progression or distant recurrence. 
  RFA was a safe procedure. Although many patients treated by 
RFA in this study were at high risk for surgical treatment because 
of advanced cirrhosis or other comorbidities, complications 
occurred in only 2.2  %   of the treatments. Other investigators have 
also  reported  low  complication  rates  of  0 – 6.1 %   ( 11,13 – 16 ).  For 
hepatic resection, morbidity rates of 38  –  47  %   have been reported 
even in recent studies (  36  –  38  ). 
  To date, percutaneous ethanol injection has been considered the 
standard in ablation (  5  ). However, randomized controlled trials 
have demonstrated the superiority of RFA (  6  –  9  ), with RFA now 
largely replacing ethanol injection. We have also shift  ed from etha-
nol injection to RFA (  10  ). At our department, RFA is currently the 
fi  rst option and ethanol injection is performed only on patients on 
whom RFA cannot be performed safely because of either entero-
biliary refl  ux, adhesion between the tumor and the gastrointestinal 
tract, or other reasons. 
  Surgical resection has been considered the treatment of choice 
for HCC. Our fi  rst option for resectable HCC was also surgery. 
However, most patients who came to our department visited us 
because they did not want surgical resection. Th   us, many patients 
in this study underwent RFA not because of unresectable tumor but 
because of refusal of surgery. Th   ose who preferred surgery would 
have directly gone to the surgical department that has extensive 
experience in hepatic resection (  38  ). 
  It is not easy to compare outcomes between RFA and surgical 
resection; the indications are diff  erent between the two treatments. 
Furthermore, indications for each treatment are diff  erent from 
institution to institution. Th   us, a case adjudged to be treatable by 
RFA or surgical resection at an institution may not be given the 
same treatment at another. Th   e best known indication criteria for 
surgical resection may be those proposed in the Barcelona Clinic 
Liver Cancer (BCLC) protocol ( 5 ), which states that surgical resec-
tion should be restricted to patients with performance status 0, 
Child-Pugh class A, single HCC, normal portal pressure, and nor-
mal serum bilirubin level. In patients satisfying those criteria, the 
5-year  survival  rate  is  expected  to  be      >    70 %   ( 30 ).  In  this  study,  237 
tumor recurrence rate exceeds 70 %  at 5 years ( 30,31 ). In this study, 
periodic follow-up detected most recurrences at limited stage. RFA 
was performed again for fi  rst recurrence in almost 90  %   of cases, 
although multimodal treatments were used in a long-term follow-
up. On the other hand, repeat resection rate for fi  rst recurrence 
has been reported to range from 10.4 to 30.6  %   (  31,32  ). Because 
RFA is less invasive than hepatic resection, iterative RFA can be 
performed for recurrence more easily. 
  Local tumor progression was found less frequently in this study 
than in other studies, having been reported to be around 10  %   at 3 
years following RFA (  13,14  ). Furthermore, diff  erent from the fi  nd-
ings in previous reports (  33,34  ), tumor size was not related to local 
tumor progression in this study. Th  ese diff  erences are probably 
because we repeated RFA until we considered we had ablated not 
only the tumor itself but also some of the liver tissue surrounding 
it. Furthermore, to avoid local tumor progression, we were more 
cautious in the treatment of larger tumors when deciding whether 
suffi   cient ablation had been performed. Only serum DCP level was 
signifi  cantly related to local tumor progression in this study. Ele-
vated serum DCP level may be related to the malignant potential 
of HCC such as the development of portal venous invasion (  35  ). 
 Th  e frequency of distant recurrence in this study was similar 
to that reported in other studies (  13  ). Among the variables sig-
nifi  cantly related to distant recurrence, tumor size, tumor number, 
serum AFP level, and serum DCP level were probably related to 
micrometastasis, which had not been detected by imaging modali-
ties before the treatment, while anti-HCV, Child-Pugh class, and 
platelet count were related to metachronous multicentric car-
cinogenesis, which developed based on underlying chronic liver 
disease. 
  From the viewpoint of survival and distant recurrence, patients 
with 2.1  –  5.0      cm tumors had signifi  cantly worse outcomes than 
those with   ≤ 2.0   cm  tumors  while  those  with  tumors      >    5.0   cm  did 
not have worse rates than those with tumors  ≤ 2   cm. Th   is is  probably 
    Table 4  .       Complications in 2,982 treatments of radiofrequency 
ablation for hepatocellular carcinoma     
        Complication       No. of complications   
      Neoplastic seeding    24 
      Liver abscess    6 
      Hemoperitoneum   12 
      Hemothorax   5 
      Symptomatic pleural effusion    1 
      Massive hepatic infarction    6 
      Gastrointestinal perforation or 
penetration 
  5 
      Hemobilia   2 
      Skin burn    1 
      Pneumothorax   3 
      Gallbladder injury    1 
      Cerebral infarction    1 The American Journal of GASTROENTEROLOGY  VOLUME 107 | APRIL 2012   www.amjgastro.com
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(20.3 % ) of 1,170 patients satisfi  ed those criteria and were thus con-
sidered good candidates for surgical resection; their 5-year survival 
rate was 75.9  %  , which appears satisfactory when compared with 
outcomes following surgical resection. Furthermore, in all 1,170 
primary HCC patients treated by RFA, 5- and 10-year survival rates 
were 60.2  %   and 27.3  %  , respectively. In patients treated by surgical 
resection, 5- and 10-year survival rates were 34.4  –  70.0  %   and 10.5  –
 52.0 % ,  respectively  ( 32,39 – 45 ).  Although  this  is  an  observational 
study with no control, survivals following RFA appear comparable 
to those reported following surgical resection. 
  Two recent randomized controlled trials showed no signifi  cant 
diff  erence in survival between RFA and surgical resection (  46,47  ). 
Several nonrandomized controlled trials reported that RFA had 
similar overall survival rates to resection (  48  –  50  ), while others 
found resection to be associated with higher survival rates ( 51 – 53 ). 
Further studies are necessary to resolve comparison of RFA with 
resection. 
  We have made strenuous eff  orts to standardize the RFA proce-
dure. Although many physicians have participated in RFA at our 
institution, the procedure was invariably performed according to 
the institutional protocol and in the presence of experienced phy-
sicians. Video recording was also used to monitor the procedure. 
Additionally, preoperative planning and postoperative evaluation 
of technique eff  ectiveness were also carried out by at least three 
physicians. We also believe that not only profi  cient practice of RFA 
but also detailed preoperative planning, cautious postoperative 
evaluation of therapeutic eff  ect, and careful follow-up are vital to 
achieve satisfactory outcomes. 
  Source population in this study may represent selection bias, 
as we performed RFA on most patients who were hospitalized at 
our department; however, many patients with unfavorable tumor 
conditions for RFA might not have been referred to us. Th  erefore, 
caution is required when extrapolating our fi  ndings to the general 
population of HCC patients. 
  A second limitation is that study population cannot be clearly 
defi  ned. Th   is study was based on daily clinical practice over a 10-
year period. Indication criteria of RFA have changed over time, 
mainly because another percutaneous ablation, that is, ethanol 
injection has also been performed. Furthermore, various treat-
ments besides percutaneous ablation were available for HCC, such 
as surgical resection and transarterial chemoembolization, with 
frequently overlapping indications. 
  One further limitation is the fact that this was a single-center 
study; these results might not be reproducible consistently in other 
settings. To extrapolate the fi  ndings in this study to patients at other 
institutions, careful consideration should be given to diff  erences in 
the indications, methods, expertise, performance of available ultra-
sound and CT equipment, and others. Treatment outcome may be 
infl  uenced by the physicians  ’   expertise and the institution  ’  s volume 
of care. We started ethanol injection in 1985 and microwave abla-
tion in 1995, that is, before the introduction of RFA. Recently, we 
have performed over 900 RFA treatments per year, which may rep-
resent a far greater number of treatments than those in most other 
institutions. We would not recommend any change in daily clinical 
practice solely on the strength of our study fi  ndings. 
  In conclusion, our 10-year clinical experience shows that RFA 
could be locally curative, resulting in survival for as long as 10 
years, and was a safe procedure. RFA might be a fi  rst-line treat-
ment for selected patients with early-stage HCC.         
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  Study  Highlights  
  WHAT IS CURRENT KNOWLEDGE 
   3  Radiofrequency ablation (RFA) has been widely performed 
for hepatocellular carcinoma (HCC). 
   3  RFA has a more reliable local antitumor effect and higher 
survival than ethanol injection. 
   3  There has been no report on 10-year outcome of RFA. 
    WHAT IS NEW HERE   
   3  Five- and 10-year survival rates in 1,170 patients with 
primary hepatocellular carcinoma (HCC) were 60.2 and 
27.3  %  , respectively. 
   3  Age, antibody to hepatitis C virus, Child-Pugh class, tumor 
size, tumor number, serum des-  γ  -carboxy-prothrombin 
level, and serum lectin-reactive   α  -fetoprotein level were 
signiﬁ  cantly related to survival. 
   3  Five- and 10-year local tumor progression rates were both 
3.2  %  . Five- and 10-year distant recurrence rates were 
74.8 and 80.8  %  , respectively.                          
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